Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Non-Randomized, Open-label, Single-arm, Multi-Center Phase III Clinical Trial to Evaluate the Efficacy and Safety of IV-Globulin SN Inj.10% in the Patients Diagnosed With Immune Thrombocytopenia (ITP).

NCT02063789 is registered in ClinicalTrials.gov with Green Cross Corporation as lead sponsor.

NCT NCT02063789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02063789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Non-Randomized, Open-label, Single-arm, Multi-Center Phase III Clinical Trial to Evaluate the Efficacy and Safety of IV-Globulin SN Inj.10% in the Patients Diagnosed With Immune Thrombocytopenia (ITP).
Lead sponsor
Green Cross Corporation
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2014
Completion date
April 30, 2016
Enrollment
81 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia